不同剂量瑞舒伐他汀对老年冠心病患者血管内皮功能的影响

Study on Metrology of Rosuvastatin Intervening on Vascular Endothelial Function of Aged Patients with Coronary Heart Disease

目的观察不同剂量瑞舒伐他汀对老年冠状动脉粥样硬化性心脏病(冠心病)患者血管内皮功能的影响。方法选取2012年1月至2014年12月解放军第一八七中心医院收治的126例老年冠心病患者,由数字生成器法分为A、B、C组,每组42例。A、B、C组患者分别给予5 mg、10 mg以及20 mg的瑞舒伐他汀,饭前服用,比较三组患者的血管内皮依赖性舒张功能(EDD)、内皮非依赖性舒张功能(EIDD)功能以及总胆固醇、内皮素等的变化。结果 A、B、C组患者治疗后的总胆固醇、内皮素均显著低于治疗前[(5.77±0.67)mmol/L比(6.52±0.47)mmol/L、(89.3±11.4)ng/L比(93.3±11.8)ng/L;(5.03±0.51)mmol/L比(6.48±0.51)mmol/L、(83.3±10.2)ng/L比(93.4±11.9)ng/L;(4.87±0.48)mmol/L比(6.53±0.45)mmol/L、(84.2±10.1)ng/L比(92.7±12.3)ng/L],EDD、EIDD均显著高于治疗前[(4.5±2.1)%比(3.4±1.1)%、(15.9±4.0)%比(15.1±3.9)%;(7.3±2.4)%比(3.5±1.0)%,(17.7±5.4)%比(15.2±3.9)%;(7.3±2.4)%比(3.5±1.1)%、(17.7±5.5)%比(15.2±4.0)%](P<0.05);治疗后A组患者的总胆固醇、内皮素显著高于B组、C组,EDD、EIDD指标显著低于B组、C组(P<0.05),B组与C组的总胆固醇、内皮素、EDD、EIDD指标比较,差异无统计学意义(P>0.05);A、B、C组患者治疗期间不良反应发生率分别为9.5%、11.9%、14.3%,三组比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀可有效缓解老年冠心病患者的血管内皮功能紊乱状况,明显改善患者的内皮依赖性血管舒张功能。

Objective To study the effect of msuvastatin intervening on vascular endothelial function of aged patients with coronary heart disease. Methods A total of 126 aged patients with coronary heart disease in PLA 187th Central Hospital from Jan. 2012 to Dec. 2014 were divided into group A（42 cases）, group B （42 cases） and group C（42 cases） randomly by computer. Patients in group A, B and C were given 5 mg, 10 mg and 20 mg rosuvastatin respectively before meals, and changes of the endothelium-dependent dilation （EDD） function, endothelium-independent dilation （EIDD） function, and the content of total cholesterol （TC） , endothelin （ET） of the three groups were compared. Results TC, ET in group A, B, C after treatment were significantly lower than before treatment [ （ 5.77 ± 0. 67 ） mmol/L vs （6.52 ± 0.47 ） mmol/L, （ 89.3 ±11.4） ng/L vs （93.3 ±11.8） ng/L; （5.03 ±0. 51 ） mmoL/L vs （6.48 ±0. 51 ） mmol/L, （83.3 ±10. 2） ng/L vs （ 93.4 ± 11.9 ） ng/L; （4.87 ± 0. 48 ） mmol/L vs （ 6. 53 ± 0. 45 ） mmol/L, （ 84. 2± 10. 1 ） ng/L vs （92.7 ± 12.3 ） ng/L ], EDD, EIDD were significantly higher than before [ （ 4.5 ±2. 1 ） % vs （ 3.4± 1.1）%,（15.9±4.0）% vs （15.1 ±3.9）%;（7.3 ±2.4）% vs （3.5 ±1.0）%,（17.7 ±5.4）% vs （15.2 ±3.9）% ;（7.3 ±2.4）% vs （3.5 ±1.1）%,（17.7±5.5）% vs （15.2 ±4.0）%]; TC, ETin group A after treatment were significantly higher than group B, C, EDD, EIDD were significantly higher than group B, C （ P 〈 0.05 ）. There were no significant differences between group B and C on the level of the TC, ET, EDD, and EIDD index（P 〉0. 05） ; during treatment,adverse reaction rates of each group were 9.5% , 11.9% and 14. 3% respectively, the difference had no statistical significance （P 〉 0. 05 ）. Conehlsion Rosuvastatin can effectively relieve the disorder of vascular endothelial function of aged patients with coronary heart disease and obviously improve the endothelium-dependent vasodilation function.